{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-Raf+Mutation-Related+Tumors",
    "query": {
      "condition": "B-Raf Mutation-Related Tumors"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 4,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T03:59:13.474Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04249843",
      "title": "Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "B-Raf Mutation-Related Tumors"
      ],
      "interventions": [
        {
          "name": "BGB-3245",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MapKure, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 109,
      "start_date": "2020-02-17",
      "completion_date": "2025-08-04",
      "has_results": false,
      "last_update_posted_date": "2025-09-11",
      "last_synced_at": "2026-05-22T03:59:13.474Z",
      "location_count": 5,
      "location_summary": "Beverly Hills, California • Boston, Massachusetts • New York, New York + 2 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04249843"
    },
    {
      "nct_id": "NCT05786924",
      "title": "Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Histiocytic Neoplasm",
        "Histiocytosis",
        "BRAF Gene Mutation",
        "BRAF V600E",
        "BRAF V600 Mutation",
        "BRAF Mutation-Related Tumors",
        "BRAF",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Lung Cancer",
        "Recurrent Lung Cancer",
        "Recurrent Lung Non-Small Cell Carcinoma",
        "NSCLC",
        "Solid Tumor",
        "Solid Carcinoma",
        "KRAS G12D",
        "KRAS G12V",
        "KRAS Mutation-Related Tumors",
        "NRAS Gene Mutation",
        "Thyroid Cancer",
        "Thyroid Carcinoma",
        "Colorectal Cancer",
        "Colorectal Carcinoma",
        "Recurrent Histiocytic and Dendritic Cell Neoplasm",
        "Brain Metastases",
        "Recurrent NSCLC",
        "KRAS G13C",
        "Acquired Resistance to KRAS G12C Inhibitor",
        "KRAS G12A",
        "KRAS G12F",
        "KRAS G12R",
        "KRAS G13D"
      ],
      "interventions": [
        {
          "name": "S241656",
          "type": "DRUG"
        },
        {
          "name": "FOLFOX6/FOLFOX7",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Panitumumab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Institut de Recherches Internationales Servier",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 554,
      "start_date": "2023-04-18",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-05-22T03:59:13.474Z",
      "location_count": 10,
      "location_summary": "Gilbert, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 7 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05786924"
    },
    {
      "nct_id": "NCT04238624",
      "title": "Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anaplastic Thyroid Cancer",
        "Thyroid Cancer",
        "BRAF Gene Mutation",
        "BRAF Mutation-Related Tumors"
      ],
      "interventions": [
        {
          "name": "Dabrafenib",
          "type": "DRUG"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2020-01-20",
      "completion_date": "2026-06-20",
      "has_results": false,
      "last_update_posted_date": "2025-07-02",
      "last_synced_at": "2026-05-22T03:59:13.474Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04238624"
    },
    {
      "nct_id": "NCT06902376",
      "title": "XL092 and Cemiplimab in BRAF WT Thyroid Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anaplastic Thyroid Cancer",
        "Thyroid Cancer",
        "BRAF Mutation-Related Tumors"
      ],
      "interventions": [
        {
          "name": "Cemiplimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "XL092",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2025-06-03",
      "completion_date": "2028-08-31",
      "has_results": false,
      "last_update_posted_date": "2025-11-05",
      "last_synced_at": "2026-05-22T03:59:13.474Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06902376"
    }
  ]
}